{"id":64308,"date":"2026-04-30T14:29:24","date_gmt":"2026-04-30T06:29:24","guid":{"rendered":"https:\/\/flcube.com\/?p=64308"},"modified":"2026-04-30T14:29:25","modified_gmt":"2026-04-30T06:29:25","slug":"lianhuan-pharmaceuticals-sglt-2-inhibitor-lh-1801-meets-primary-endpoint-in-phase-iii-type-2-diabetes-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64308","title":{"rendered":"Lianhuan Pharmaceutical&#8217;s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial"},"content":{"rendered":"\n<p><strong>Jiangsu Lianhuan Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600513:SHA\">SHA: 600513<\/a>) announced that its <strong>Phase III clinical study<\/strong> for <strong>LH-1801<\/strong>, a <strong>Category 1 innovative drug<\/strong> and <strong>novel SGLT-2 inhibitor<\/strong>, has been <strong>unblinded with preliminary results indicating the primary endpoint has been met<\/strong>. The trial evaluated LH-1801 in combination with metformin for the treatment of <strong>type 2 diabetes mellitus (T2DM)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-milestone\">Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513)<\/td><\/tr><tr><td><strong>Drug Classification<\/strong><\/td><td>Category 1 innovative drug (China&#8217;s highest innovation designation)<\/td><\/tr><tr><td><strong>Study Phase<\/strong><\/td><td>Phase III clinical trial<\/td><\/tr><tr><td><strong>Study Status<\/strong><\/td><td>Unblinded with primary endpoint met<\/td><\/tr><tr><td><strong>Combination Therapy<\/strong><\/td><td>LH-1801 + metformin<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Type 2 diabetes mellitus (T2DM)<\/td><\/tr><tr><td><strong>Development Partnership<\/strong><\/td><td>Co-developed with Shanghai Institute of Materia Medica, Chinese Academy of Sciences<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Compound<\/strong>: <strong>LH-1801<\/strong> \u2013 novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Selective inhibition of SGLT-2 in renal proximal tubules, promoting urinary glucose excretion and lowering blood glucose levels<\/li>\n\n\n\n<li><strong>Therapeutic Class<\/strong>: Represents China&#8217;s domestic innovation in the established SGLT-2 inhibitor class, which includes global blockbusters like empagliflozin, dapagliflozin, and canagliflozin<\/li>\n\n\n\n<li><strong>Development Strategy<\/strong>: Combination with metformin addresses standard-of-care sequencing in T2DM management<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-context\">Clinical Development Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Patient Population<\/strong><\/td><td>Adults with type 2 diabetes mellitus requiring dual therapy<\/td><\/tr><tr><td><strong>Comparator Standard<\/strong><\/td><td>Metformin monotherapy or other SGLT-2 inhibitor combinations<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Not specified in announcement, but typically HbA1c reduction at 24-52 weeks<\/td><\/tr><tr><td><strong>Regulatory Pathway<\/strong><\/td><td>Category 1 designation enables expedited review processes in China<\/td><\/tr><tr><td><strong>Market Timing<\/strong><\/td><td>Enters mature but growing SGLT-2 inhibitor market with domestic innovation premium<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications-amp-market-outlook\">Strategic Implications &amp; Market Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Domestic Innovation Leadership<\/strong>: LH-1801 represents China&#8217;s push for homegrown innovative pharmaceuticals in chronic disease management<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong>: China&#8217;s T2DM market exceeds 140 million patients, with SGLT-2 inhibitors capturing increasing market share due to cardiovascular and renal benefits<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: As a domestically developed Category 1 drug, LH-1801 may receive preferential reimbursement and hospital formulary placement<\/li>\n\n\n\n<li><strong>Commercial Infrastructure<\/strong>: Lianhuan&#8217;s established presence in China&#8217;s pharmaceutical market provides ready commercialization capabilities<\/li>\n\n\n\n<li><strong>Pipeline Validation<\/strong>: Success validates the company&#8217;s research collaboration model with academic institutions like the Shanghai Institute of Materia Medica<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development outcomes, regulatory timelines, and commercial potential for LH-1801. Actual results may differ due to risks including final clinical data analysis, regulatory decisions, and competitive dynamics in the SGLT-2 inhibitor market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600513_20260430_IR6M.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600513_20260430_IR6M.\"><\/object><a id=\"wp-block-file--media-7fcc669e-42bd-4ab1-bdb7-15b0e5ffca3a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600513_20260430_IR6M.pdf\">600513_20260430_IR6M<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/600513_20260430_IR6M.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7fcc669e-42bd-4ab1-bdb7-15b0e5ffca3a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced that its Phase III clinical study for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,39,3245,4125],"class_list":["post-64308","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-diabetes","tag-lianhuan-pharmaceutical","tag-sha-600513"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lianhuan Pharmaceutical&#039;s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced that its Phase III clinical study for LH-1801, a Category 1 innovative drug and novel SGLT-2 inhibitor, has been unblinded with preliminary results indicating the primary endpoint has been met. The trial evaluated LH-1801 in combination with metformin for the treatment of type 2 diabetes mellitus (T2DM).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64308\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lianhuan Pharmaceutical&#039;s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced that its Phase III clinical study for LH-1801, a Category 1 innovative drug and novel SGLT-2 inhibitor, has been unblinded with preliminary results indicating the primary endpoint has been met. The trial evaluated LH-1801 in combination with metformin for the treatment of type 2 diabetes mellitus (T2DM).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64308\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-30T06:29:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-30T06:29:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64308#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64308\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lianhuan Pharmaceutical&#8217;s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial\",\"datePublished\":\"2026-04-30T06:29:24+00:00\",\"dateModified\":\"2026-04-30T06:29:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64308\"},\"wordCount\":395,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"Diabetes\",\"Lianhuan Pharmaceutical\",\"SHA: 600513\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64308#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64308\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64308\",\"name\":\"Lianhuan Pharmaceutical's SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-30T06:29:24+00:00\",\"dateModified\":\"2026-04-30T06:29:25+00:00\",\"description\":\"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced that its Phase III clinical study for LH-1801, a Category 1 innovative drug and novel SGLT-2 inhibitor, has been unblinded with preliminary results indicating the primary endpoint has been met. The trial evaluated LH-1801 in combination with metformin for the treatment of type 2 diabetes mellitus (T2DM).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64308#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64308\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64308#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lianhuan Pharmaceutical&#8217;s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lianhuan Pharmaceutical's SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced that its Phase III clinical study for LH-1801, a Category 1 innovative drug and novel SGLT-2 inhibitor, has been unblinded with preliminary results indicating the primary endpoint has been met. The trial evaluated LH-1801 in combination with metformin for the treatment of type 2 diabetes mellitus (T2DM).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64308","og_locale":"en_US","og_type":"article","og_title":"Lianhuan Pharmaceutical's SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial","og_description":"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced that its Phase III clinical study for LH-1801, a Category 1 innovative drug and novel SGLT-2 inhibitor, has been unblinded with preliminary results indicating the primary endpoint has been met. The trial evaluated LH-1801 in combination with metformin for the treatment of type 2 diabetes mellitus (T2DM).","og_url":"https:\/\/flcube.com\/?p=64308","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-30T06:29:24+00:00","article_modified_time":"2026-04-30T06:29:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64308#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64308"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lianhuan Pharmaceutical&#8217;s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial","datePublished":"2026-04-30T06:29:24+00:00","dateModified":"2026-04-30T06:29:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64308"},"wordCount":395,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","Diabetes","Lianhuan Pharmaceutical","SHA: 600513"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64308#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64308","url":"https:\/\/flcube.com\/?p=64308","name":"Lianhuan Pharmaceutical's SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-30T06:29:24+00:00","dateModified":"2026-04-30T06:29:25+00:00","description":"Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA: 600513) announced that its Phase III clinical study for LH-1801, a Category 1 innovative drug and novel SGLT-2 inhibitor, has been unblinded with preliminary results indicating the primary endpoint has been met. The trial evaluated LH-1801 in combination with metformin for the treatment of type 2 diabetes mellitus (T2DM).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64308#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64308"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64308#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lianhuan Pharmaceutical&#8217;s SGLT-2 Inhibitor LH-1801 Meets Primary Endpoint in Phase III Type 2 Diabetes Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64308"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64308\/revisions"}],"predecessor-version":[{"id":64311,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64308\/revisions\/64311"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}